<DOC>
	<DOCNO>NCT01180036</DOCNO>
	<brief_summary>The primary outcome study determine whether B cell target Rituximab effective Cyclosporine inducing long term remission proteinuria .</brief_summary>
	<brief_title>MEmbranous Nephropathy Trial Of Rituximab</brief_title>
	<detailed_description>In IMN , experimental data suggest B cell involve pathogenesis disease . To date , best proven therapy patient MN consist combine use corticosteroid cyclophosphamide ( CYC ) . Since mechanism action CYC include suppression various stage B cell cycle include B cell activation , proliferation , differentiation inhibition immunoglobulin secretion , lend credence hypothesis B cell abnormality involve pathogenesis MN . Given key role IgG antibodies MN , reasonable postulate suppression antibody production deplete B cell may improve even resolve glomerular pathology reflect reduction proteinuria . Thus , case could make use agent capable selectively deplete B cell , therefore halt production immunoglobulin antigens potentially present glomerulus . This approach could stop initiate sequence pathogenic event result resolution . The P.I . believe application selective B cell target Rituximab ( RTX ) prove least equal , even superior , production short term long term control NS safer current therapeutic regimen use treat MN . Based rationale , conduct pilot trial 15 newly-biopsied patient ( &lt; 3 year ) IMN proteinuria &gt; 5g/24h despite ACEi/ARB use &gt; 3months systolic BP &lt; 130mmHg . Mean baseline creatinine 1.4 mg/dl . Thirteen males 2 female , median age 47 ( range 33-63 ) , treat RTX ( 1g ) day 1 15 . At six month , patient remain proteinuria &gt; 3g/24 receive second identical course RTX . Baseline proteinuria 13.0±5.7g/24h ( range 8.4-23.5 ) decrease 6.0±7.0 g/24h ( range 0.2-20 ) 12 month ( mean ± SD ) . In fourteen patient complete 12 month follow-up complete remission ( proteinuria &lt; 0.3g/24h ) achieve 2 patient partial remission ( &lt; 3g/24h ) 7 patient . In 5 7 patient , proteinuria &lt; 1.5g/24h follow 18 month show 3 7 patient PR achieve CR proteinuria . Five patient respond . The mean drop proteinuria baseline 12 month 6.2± 5.1g ( p=.002 , pair t-test ) . There limited number minor side-effects . Initial CD20+ B cell depletion see patient . However , 3 month , CD20+ B cell start recover five patient &gt; 35 cells/µl ( range 35-152 ) . ( 50 ) These data contrast previous work Ruggenenti et al . use RTX give weekly ( 375 mg/m2 ) 4 week . Pharmacokinetic ( PK ) analysis show RTX level 2-dose regimen 50 % low compare non-proteinuric patient , could potentially result undertreatment . Based result , recently conduct study postulate patient MN , 4 weekly dos RTX would result effective B cell depletion , high remission rate maintain safety profile compare patient treat RTX dose 1g x 2 . Twenty patient ( 11 failure prior therapy ) MN proteinuria &gt; 5g/24h receive RTX ( 375mg/m2 x 4 ) , retreatment 6 month regardless proteinuria response . A detailed PK conduct simultaneously along immunological analysis adaptive immune compartment ( T B cell ) ascertain impact RTX lymphocyte subpopulation . Baseline proteinuria 11.9±4.9g/24h decrease 4.2±3.8g/24h 2.0±1.7g/24h 12 24 month , respectively ( p &lt; 0.001 ) creatinine clearance increase 72.4±33 baseline 88.4 ±31.5 ml/min/1.73m2 24 month ( p=0.02 ) . Of 18 patient complete 24-months follow , 4 complete remission , 12 partial remission ( CR + PR = 80 % ) , 1 limited response ( &gt; 50 % drop P &gt; 3.5g/24h ) 1 patient relapse . When interpret result take account &gt; 50 % patient fail previous immunosuppressive therapy . This study also emphasize proteinuria reduce gradually may take several month reach nadir observation agreement previous report patient MN treat prednisone combination cytotoxic agent without short-term toxicity see alkylating agent . Kidney function remain stable improved patient . Serum RTX level similar obtain 2 dos RTX . Four 4 dos RTX result effective B cell depletion proteinuria reduction basically identical result obtain use RTX 1000mg day 1 15 . Thus , believe particular dose regimen retreatment 6 month use randomized-control trial compare RTX Cyclosporine ( standard care IMN US ) . We believe RTX prove equal superior Cyclosporine treatment MN could represent new standard care patient disease</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion Criteria Idiopathic MN diagnostic biopsy Female , must postmenopausal , surgically sterile practice medically approve method contraception ( birthcontrol pill ) Must prednisone mycophenolate mofetil &gt; 1 month alkylating agent &gt; 6 month . ACEi and/or ARB , &gt; 3 month prior randomization adequate blood pressure ( target BP &lt; 130/80 mmHg &gt; 75 % reading , subject BP &lt; 140/80 mmHg &gt; 75 % reading eligible ) . Patients document evidence &gt; 3 month treatment maximal angiotensin II blockade , HMGCoA reductase inhibitor , BP control ( BP &lt; 140/80 mmHg &gt; 75 % reading ) remain proteinuria &gt; 5g/24h may enter randomize RTX/CSA without need runin/conservative phase study . Proteinuria &gt; 5g/24h two 24hour urine collection collect within 14 day Estimated GFR ≥40 ml/min/1.73m2 take ACEi/ARB therapy OR quantify endogenous creatinine clearance &gt; 40 ml/min/1.73m2 base 24hour urine collection . Exclusion Criteria Presence active infection secondary cause MN ( e.g . hepatitis B , SLE , medication , malignancy ) . Testing HIV , Hepatitis B C occur &lt; 2 year prior enrollment study . Type 1 2 diabetes mellitus : exclude proteinuria secondary diabetic nephropathy . Patients recent history steroid induce diabetes evidence renal biopsy perform within 6 month entry study eligible enrollment . Pregnancy breast feed safety reason History resistance CSA ( calcineurin inhibitor , e.g . tacrolimus ) , RTX alkylating agent ( e.g . Cytoxan ) . Patients previously respond CSA/CNI , RTX alkylating agent either CR PR relapse CSA/CNI 3 month relapse RTX alkylating agent 6 month eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Membranous Nephropathy</keyword>
</DOC>